NCT05919147View on ClinicalTrials.gov

The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Lung Cancer
Interventions
DRUG

Pioglitazone 45 mg

The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks.

DRUG

Placebo

Placebo will have the same appearance as the active drug.

Trial Locations (1)

70808

Pennington Biomedical Research Center, Baton Rouge

All Listed Sponsors
lead

Pennington Biomedical Research Center

OTHER

NCT05919147 - The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia | Biotech Hunter | Biotech Hunter